Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses
Journal of Infection and Public Health · 2025
DOI: 10.1016/j.jiph.2025.102676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Infection and Public Health, 2025. Verfasst von Fatemeh Ashrafian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address: fatemeh.ashrafian24@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pasteur Institute of Iran.
Abstract (Originalsprache)
BACKGROUND: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran. METHODS: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects. The durability of anti-spike, anti-nucleocapsid (NCP), neutralizing antibody, and interferon-γ (IFN-γ) was evaluated at least 6 months after the last vaccination, as well as 60 and 120 days after it, in individuals who received two or three doses of the COVID-19 vaccine. Furthermore, the evaluation of humoral and cellular response was performed before the fourth dose (second booster) as well as 21 and 60 days thereafter. RESULTS: The 3-dose group showed significantly higher levels of anti-spike, neutralizing antibodies, and IFN-γ compared to the 2-dose group. Both the 2-dose and 3-dose groups experienced a slight decrease in the dynamic of SARS-CoV-2 Abs, though the associated levels remained within a positive range. After receiving the fourth dose of PastoCovac, most participants had significantly high levels of anti-spike, neutralizing antibodies, and IFN-γ, regardless of the type of three-dose regimen they had previously received. The average antibody titer decreased after 60 days from the fourth dose, but remained relatively stable during the follow-up period. CONCLUSION: This study found that the level of anti-SARS-CoV-2 antibodies and IFN-γ, as well as their durability, were still within a positive range in 2-dose and 3-dose vaccinated groups over the long-term follow-up. Furthermore, PastoCovac vaccine enhanced humoral and cellular immune responses and could be recommended as a booster dose for individuals previously vaccinated with any previously administered COVID-19 vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address: fatemeh.ashrafian24@gmail.com.
- Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: mostafavaziri1985@gmail.com.
- Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran. Electronic address: mostafaviehsan@gmail.com.
- Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran; Department of Biostatistics and Epidemiology, School of Public Health, Kerman University…
- Vaccination Department, Pasteur Institute of Iran, Tehran, Iran. Electronic address: sarahdahmardeh@gmail.com.
- Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address: Anahita.bavand@gmail.com.
Förderung
- Pasteur Institute of Iran
Zitieren
APA
Ashrafian, F., Salehi-Vaziri, M., Mostafavi, E., Maghsoudi, S. H., Dahmardeh, S., Bavand, A., Moradi, L., Tajmehrabi Namini, P., Zali, M., Tahmasebi, Z., Sadat Larijani, M., & Ramezani, A. (2025). Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2025.102676
Vancouver
Ashrafian F, Salehi-Vaziri M, Mostafavi E, Maghsoudi SH, Dahmardeh S, Bavand A, et al. Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses. Journal of Infection and Public Health. 2025. doi:10.1016/j.jiph.2025.102676
BibTeX
@article{Ashrafian2025,
author = {Ashrafian, Fatemeh and Salehi-Vaziri, Mostafa and Mostafavi, Ehsan and Maghsoudi, Saiedeh Haji and Dahmardeh, Sarah and Bavand, Anahita and Moradi, Ladan and Tajmehrabi Namini, Parinaz and Zali, Mahsan and Tahmasebi, Zahra and Sadat Larijani, Mona and Ramezani, Amitis},
title = {Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses},
journal = {Journal of Infection and Public Health},
year = {2025},
doi = {10.1016/j.jiph.2025.102676}
}
EUVIMED